Blood and Oral Fluid Cannabinoid Profiles of Frequent and Occasional Cannabis Smokers.


Journal

Journal of analytical toxicology
ISSN: 1945-2403
Titre abrégé: J Anal Toxicol
Pays: England
ID NLM: 7705085

Informations de publication

Date de publication:
17 Sep 2021
Historique:
received: 19 03 2021
revised: 14 06 2021
accepted: 25 06 2021
pubmed: 27 6 2021
medline: 21 9 2021
entrez: 26 6 2021
Statut: ppublish

Résumé

Increased prevalence of cannabis consumption and impaired driving are a growing public safety concern. Some states adopted per se driving laws, making it illegal to drive with more than a specified blood concentration of ∆9-tetrahydrocannabinol (THC) in a biological fluid (typically blood). Blood THC concentrations decrease significantly (∼90%) with delays in specimen collection, suggesting the use of alternative matrices, such as oral fluid (OF). We characterized 10 cannabinoids' concentrations, including THC metabolites, in blood and OF from 191 frequent and occasional users by liquid chromatography with tandem mass spectrometry for up to 6 h after ad libitum smoking. Subjects self-titrated when smoking placebo, 5.9 or 13.4% THC cannabis. Higher maximum blood THC concentrations (Cmax) were observed in individuals who received the 5.9% THC versus the 13.4% THC plant material. In blood, the Cmax of multiple analytes, including THC and its metabolites, were increased in frequent compared to occasional users, whereas there were no significant differences in OF Cmax. Blood THC remained detectable (≥5 ng/mL) at the final sample collection for 14% of individuals who smoked either the 5.9 or 13.4% THC cigarette, whereas 54% had detectable THC in OF when applying the same cutoff. Occasional and frequent cannabis users' profiles were compared, THC was detectable for significantly longer duration in blood and OF from frequent users. Detection rates between frequent and occasional users at multiple per se cutoffs showed larger differences in blood versus OF. Understanding cannabinoid profiles of frequent and occasional users and the subsequent impact on detectability with current drug per se driving limits is important to support forensic interpretations and the development of scientifically supported driving under the influence of cannabis laws.

Identifiants

pubmed: 34173005
pii: 6309824
doi: 10.1093/jat/bkab078
doi:

Substances chimiques

Cannabinoids 0
Dronabinol 7J8897W37S

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

851-862

Subventions

Organisme : State of California Assembly Bill 266

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Melissa A Hoffman (MA)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Jacqueline A Hubbard (JA)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Philip M Sobolesky (PM)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Breland E Smith (BE)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Raymond T Suhandynata (RT)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Sandra Sanford (S)

Department of Psychiatry, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Emily G Sones (EG)

Department of Psychiatry, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Shannon Ellis (S)

Department of Cognitive Science, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.
Halıcıoğlu Data Science Institute, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Anya Umlauf (A)

Department of Psychiatry, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Marilyn A Huestis (MA)

Institute of Emerging Health Professions, Thomas Jefferson University, 130 South 9th Street Philadelphia, PA 19107, USA.

David J Grelotti (DJ)

Department of Psychiatry, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Igor Grant (I)

Department of Psychiatry, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Thomas D Marcotte (TD)

Department of Psychiatry, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

Robert L Fitzgerald (RL)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH